Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety study of vatiquinone in previously treated subjects with inherited mitochondrial disease
2022-000375-39Phase 3Terminated
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vatiquinone in Mitochondriopathy, Leigh syndrome, Alpers disease and 3 more, sponsored by PTC Therapeutics, Inc. Primary endpoint: Safety endpoints. Started Sep 2022; status: terminated.
02
Drugs
vatiquinone
03
Conditions
MitochondriopathyLeigh syndromeAlpers diseasemitochondrial encephalomyopathiesmyoclonic epilepsy with ragged-red fibers (MERRF)
Beyond the preview
Go deeper on 2022-000375-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000375-39.